Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD), and the proportion of patients with ESRD who have diabetes (most of whom have T2DM) has increased over the past ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

The basis for the prevention of diabetic nephropathy is the treatment of its known risk factors: hypertension, hyperglycemia, smoking, and dyslipidemia. These are also risk factors for ...

Idiopathic Membranous Nephropathy Treatment Market is projected to witness substantial growth over the next few years, driven ...

In the phase III study, among the first 250 patients with IgA nephropathy who underwent randomization, the adjusted geometric mean 24-hour urinary protein-to-creatinine ratio (UPCR) was 38.3% (95% ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase II trial revealed that felzartamab, an ...

Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- A novel drug significantly reduced IgA nephropathy-related proteinuria, according to interim findings of ...

IgA nephropathy is the most common primary glomerulonephritis and contributes to kidney failure. Growing evidence exists that the overactivation of the lectin pathway contributes to the pathogenesis ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

UK MHRA grants marketing authorization to sparsentan to treat adult patients with primary immunoglobulin A nephropathy: United Kingdom Wednesday, November 20, 2024, 14:00 Hrs [IST ...